The 2024 ICAO Symposium on Non-CO2 Aviation Emissions will be aiming at raising awareness of all interested parties on non-CO2 emissions from aviation operations and creating synergies between different stakeholders.
While there is substantial understanding of the components of aviation's climate impacts, particularly CO2 emissions, important uncertainties remain in quantifying some of aviation's non-CO2 climate terms and in the underlying physical processes. As the science evolves, ICAO continues to assess the situation, identifying where action can be taken.
This three-day event will be held as an in-person event from 16 to 18 September 2024, in ICAO Headquarters, Montréal, Canada and will focus on taking stock of the scientific knowledge on non-CO2 effects and sharing the work undertaken by ICAO and all relevant stakeholders, as well as exploring future activities and measures to potentially mitigate and address these effects, considering the existing scientific uncertainties.
All stakeholders who wish to take this opportunity for showcasing their products and services from around the world are invited to fill in the form on the sponsors page to obtain the full list of sponsorship and exhibition opportunities.
Registrations are now closed. If you are not registered yet and want to attend the Symposium, the On-site Registration and Badge Collection Hours will be the following:
Thursday, 12 September from 14:00 to 17:00 hours
Monday, 16 September from 07:30 to 10:30 hours
Meetings of the International Civil Aviation Organization (ICAO) during the Mpox Public Health Emergency
The International Civil Aviation Organization (ICAO) has reviewed the World Health Organization (WHO) guidelines regarding public gatherings in light of the current Mpox outbreak: Public health advice for gatherings during the current Mpox outbreak (who.int).
As of 19 August 2024, and based on a thorough risk assessment of current available information, ICAO has determined that there is no necessity to postpone or cancel its scheduled meetings. The Organization will continue to monitor the situation and adhere to the advice of WHO for Member States, authorities and event organizers. This includes implementing preventive and management measures for mpox through collaboration between the ICAO Medical Services and the Canadian Public Health Authority.
In addition, ICAO has revised its risk mitigation strategies in line with the United Nations Medical Directors’ Risk Mitigation Plan for Mpox to further ensure the safety of all participants.
ACTIONS BY MEETING PARTICIPANTS
- Do not attend a meeting should they exhibit any signs or symptoms compatible with mpox.
- Seek immediate medical attention and notify ICAO Medical Services without delay by contacting +1 (514) 315-1955 or medcen [at] icao.int (medcen[at]icao[dot]int), should they develop any signs or symptoms compatible.
- Avoid close contact with individuals showing signs or symptoms compatible with mpox.
- Utilize hand disinfection stations provided throughout the ICAO premises.
Note 1. Signs and symptoms: Mpox symptoms may include a skin rash on the face, hands, and feet, acute fever (>38.5°C), swollen lymph nodes, headache, muscle aches, back pain, severe weakness and extreme fatigue.
Note 2. Face masks: Currently, there are no recommendations or requirements for wearing face masks for mpox as it has not been recommended by WHO for mpox. The decision to wear a mask is left to individual discretion as it could mitigate the transmission of other airborne infections or protect high-risk individuals.
Note 3. Mass vaccination: It is not recommended for mpox currently. WHO’s guidance on mpox vaccination is available here.